Acquired by Merck in November 2021
XLRN - Acceleron Pharma Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
XLRN price evolution
XLRN
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $336.46 | $336.2 | $455.51 | $670.95 |
| Short term investments | $254.11 | $287.15 | $231.74 | $178.95 |
| Net receivables | $34.2 | $27.94 | $25.21 | $26.1 |
| Inventory | ||||
| Total current assets | $696.61 | $717.77 | $737.61 | $893.27 |
| Long term investments | $61.95 | $89.19 | $108.19 | $7.58 |
| Property, plant & equipment | $27.75 | $27.38 | $28.27 | $29.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $91.24 | $118.28 | $138.18 | $39.07 |
| Total investments | $316.06 | $376.35 | $339.93 | $186.54 |
| Total assets | $787.85 | $836.05 | $875.79 | $932.34 |
| Current liabilities | ||||
| Accounts payable | $5.09 | $9.44 | $4.46 | $8.47 |
| Deferred revenue | ||||
| Short long term debt | $8.16 | $7.55 | $7.28 | $7.01 |
| Total current liabilities | $57.37 | $59.48 | $49.82 | $60.16 |
| Long term debt | $11.95 | $13.17 | $15.14 | $17.07 |
| Total noncurrent liabilities | $12.32 | $13.54 | $15.14 | $17.07 |
| Total debt | $20.11 | $20.72 | $22.43 | $24.08 |
| Total liabilities | $69.69 | $73.02 | $64.96 | $77.23 |
| Shareholders' equity | ||||
| Retained earnings | -$1074.89 | -$1004.43 | -$940.91 | -$877.44 |
| Other shareholder equity | -$0.4 | -$0.41 | -$0.42 | -$0.29 |
| Total shareholder equity | $718.15 | $763.03 | $810.83 | $855.11 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $670.95 | $237.68 | $145.65 | $101.28 |
| Short term investments | $178.95 | $193.69 | $147.26 | $177.08 |
| Net receivables | $26.1 | $8.55 | $7.04 | $3.57 |
| Inventory | ||||
| Total current assets | $893.27 | $449.92 | $306.01 | $285.24 |
| Long term investments | $7.58 | $22.48 | $95.72 | |
| Property, plant & equipment | $29.76 | $30.72 | $7.11 | $6.97 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $39.07 | $54.99 | $8.81 | $103.93 |
| Total investments | $186.54 | $216.17 | $147.26 | $272.8 |
| Total assets | $932.34 | $504.91 | $314.82 | $389.18 |
| Current liabilities | ||||
| Accounts payable | $8.47 | $2.29 | $0.42 | $1.09 |
| Deferred revenue | $0.28 | $3.7 | ||
| Short long term debt | $7.01 | $6.18 | ||
| Total current liabilities | $60.16 | $33.37 | $18.91 | $16.75 |
| Long term debt | $17.07 | $20.2 | ||
| Total noncurrent liabilities | $17.07 | $22.06 | $3.87 | $7.21 |
| Total debt | $24.08 | $26.38 | ||
| Total liabilities | $77.23 | $55.43 | $22.78 | $23.96 |
| Shareholders' equity | ||||
| Retained earnings | -$877.44 | -$711.41 | -$586.55 | -$473.02 |
| Other shareholder equity | -$0.29 | $0.02 | -$0.56 | -$0.9 |
| Total shareholder equity | $855.11 | $449.48 | $292.04 | $365.22 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $34.2 | $27.94 | $24.76 | $25.87 |
| Cost of revenue | ||||
| Gross Profit | $34.2 | $27.94 | $24.76 | $25.87 |
| Operating activities | ||||
| Research & development | $59.72 | $56.13 | $57.3 | $57.25 |
| Selling, general & administrative | $45.11 | $35.47 | $31.06 | $26.21 |
| Total operating expenses | $104.83 | $91.6 | $88.36 | $83.46 |
| Operating income | -$70.63 | -$63.66 | -$63.6 | -$57.59 |
| Income from continuing operations | ||||
| EBIT | -$70.45 | -$63.51 | -$63.47 | -$57.41 |
| Income tax expense | $0.01 | $0.01 | $0.01 | -$0.01 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$70.47 | -$63.52 | -$63.47 | -$57.4 |
| Income (for common shares) | -$70.47 | -$63.52 | -$63.47 | -$57.4 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $92.52 | $73.99 | $13.99 | $13.48 |
| Cost of revenue | ||||
| Gross Profit | $92.52 | $73.99 | $13.99 | $13.48 |
| Operating activities | ||||
| Research & development | $173.92 | $153.95 | $103.9 | $89.73 |
| Selling, general & administrative | $85.91 | $56.48 | $34.5 | $33.74 |
| Total operating expenses | $259.83 | $210.44 | $138.41 | $123.46 |
| Operating income | -$167.31 | -$136.44 | -$124.41 | -$109.98 |
| Income from continuing operations | ||||
| EBIT | -$166.01 | -$124.92 | -$118.9 | -$108.42 |
| Income tax expense | $0.02 | -$0.06 | -$0.03 | $0.03 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$166.03 | -$124.86 | -$118.87 | -$108.45 |
| Income (for common shares) | -$166.03 | -$124.86 | -$118.87 | -$108.45 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$70.47 | -$63.52 | -$63.47 | -$57.4 |
| Operating activities | ||||
| Depreciation | $2.82 | $2.65 | $2.6 | $2.52 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.42 | $13.48 | $15.63 | $8.43 |
| Total cash flows from operations | -$70.89 | -$84.42 | -$67.92 | -$38.13 |
| Investing activities | ||||
| Capital expenditures | -$2.41 | -$0.97 | -$0.92 | -$0.9 |
| Investments | $59.2 | -$36.16 | -$150.29 | -$28.7 |
| Total cash flows from investing | $56.79 | -$37.13 | -$151.21 | -$29.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $14.15 | $2.23 | $3.7 | $9 |
| Net borrowings | ||||
| Total cash flows from financing | $14.15 | $2.23 | $3.7 | $9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.06 | -$119.31 | -$215.44 | -$58.73 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | -$166.03 | -$124.86 | -$118.87 | -$108.45 |
| Operating activities | ||||
| Depreciation | $9.61 | $9.08 | $3.75 | $2.83 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $30.24 | $23 | $24.57 | $28.25 |
| Total cash flows from operations | -$130.33 | -$93.8 | -$94.71 | -$76.73 |
| Investing activities | ||||
| Capital expenditures | -$4.2 | -$3.29 | -$2.59 | -$4.4 |
| Investments | $29.8 | -$68 | $125.52 | -$59.97 |
| Total cash flows from investing | $25.6 | -$71.29 | $122.93 | -$64.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $538.01 | $258.72 | $17.02 | $220.52 |
| Net borrowings | -$0.14 | |||
| Total cash flows from financing | $538.01 | $258.72 | $16.15 | $220.3 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $433.27 | $93.63 | $44.37 | $79.2 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 61.16M |
| Revenue | $112.76M |
|---|---|
| EBITDA | -$244.24M |
| EBIT | -$254.83M |
| Net Income | -$254.85M |
| Revenue Q/Q | 51.58% |
| Revenue Y/Y | 6.39% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 11.75 |
| Cash/Share | 5.50 |
| EPS | -$4.17 |
|---|---|
| ROA | -29.70% |
| ROE | -32.39% |
| Debt/Equity | 0.09 |
|---|---|
| Net debt/EBITDA | 1.09 |
| Current ratio | 12.14 |
| Quick ratio | 12.14 |